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Amyloid  (A) and tau protein are both implicated in memory impairment, mild cognitive impairment (MCI), and early Alzheimer’s
disease (AD), but whether and how they interact is unknown. Consequently, we asked whether tau protein is required for the robust
phenomenonofA-induced impairment of hippocampal long-termpotentiation (LTP), awidely accepted cellularmodel ofmemory.We
used wild-type mice and mice with a genetic knock-out of tau protein and recorded field potentials in an acute slice preparation. We
demonstrate that the absence of tau protein prevents A-induced impairment of LTP. Moreover, we show that A increases tau phos-
phorylation and that a specific inhibitor of the tau kinase glycogen synthase kinase 3 blocks the increased tau phosphorylation induced by
A andpreventsA-induced impairment of LTP inwild-typemice. Together, these findings show that tauprotein is required forA to impair
synaptic plasticity in the hippocampus and suggest that the A-induced impairment of LTP ismediated by tau phosphorylation.We conclude
that preventing the interaction betweenA and tau could be a promising strategy for treating cognitive impairment inMCI and early AD.
Introduction
Amyloid  (A) and tau protein both have well established roles
in Alzheimer’s disease (AD), forming the two hallmark patholo-
gies visible in postmortem AD brains as amyloid plaques and
neurofibrillary tangles (NFTs), respectively (Hardy and Selkoe,
2002; Small and Duff, 2008). A plays a central role in disease
pathogenesis, being implicated in the synaptic dysfunction that is
considered a major cellular mechanism underlying the cognitive
deficits in patients with mild cognitive impairment (MCI) and
early AD (Selkoe, 2002). Plaque formation is preceded by ele-
vated levels of soluble, low-N oligomers of A, and evidence
suggests it is these that are responsible for synaptic dysfunction
(Lue et al., 1999; Hardy and Selkoe, 2002). Acute exposure to
synthetic or naturally secreted A has been shown to impair hip-
pocampal long-term potentiation (LTP) (Cullen et al., 1997;
Lambert et al., 1998; Walsh et al., 2002; Wang et al., 2004;
Townsend et al., 2006;Wei et al., 2010), a widely accepted cellular
model of learning and memory (Bliss and Collingridge, 1993).
Tau protein may also play a crucial role in the cognitive de-
cline in MCI and early AD. In the medial temporal lobe, the first
area to be affected in AD, NFTs are elevated and their numbers in
the hippocampal CA1 correlate with memory decline (Markes-
bery et al., 2006). Nevertheless, it has been suggested that tau
intermediates are more important for the cognitive decline than
the tangles themselves (Santacruz et al., 2005).
Thus, A and tau are both fundamental in the early stages of
AD, but whether and how these two proteins interact is not yet
established. Evidence for an important interaction includes the
protection of tau-depleted neurons from A-induced neurode-
generation in culture (Rapoport et al., 2002). Moreover, the cogni-
tive deficits that are seen in human amyloid precursor protein
(hAPP)-overexpressingmice (Hsiaoetal., 1996)areabsent inhAPP-
overexpressing mice with a genetic knock-out of tau protein (Rob-
erson et al., 2007). Therefore, to further investigate a possible
interaction between A and tau and so help elucidate the mecha-
nismunderlying thecognitivedecline inMCIandearlyAD,weasked
whether tau is required for theA-mediated impairment of LTP in the
hippocampus, one of the earliest regions affected in AD (Braak and
Braak, 1991). For this, we used both wild-type mice and mice with a
genetic knock-out of tauprotein (Tau/mice) (Dawson et al., 2001).
To investigate a possible molecular pathway for this interac-
tion, we tested whether glycogen synthase kinase 3 (GSK-3) is
involved in the A-induced impairment of LTP. GSK-3 is a
serine/threonine kinase known to phosphorylate tau protein
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(Ishiguro et al., 1993) and to play a role in both synaptic plasticity
(Hooper et al., 2007) and A-induced and tau-mediated neuro-
degeneration (Tackenberg and Brandt, 2009). If GSK-3 is in-
volved in an interaction betweenA and tau, inhibition ofGSK-3
could be a promising therapeutic strategy for MCI and early AD.
Materials andMethods
Mice. Animal care and experimental procedures were conducted in ac-
cordance with UK Home Office regulations under the Animals (Scien-
tific Procedures) Act of 1986. Animals had access to food and water ad
libitum. Holding facilities were maintained at a temperature of 22°C,
humidity of 60–70%, and with a 12 h light/dark cycle. We used 4- to
6-month-old Tau/ mice on a C57BL/6J background (Dawson et al.,
2001) and age-matched C57BL/6J mice purchased from Charles River
Laboratories. All mice were housed in the same animal facility under the
same conditions for at least 2 weeks before experiments commenced.
Mice of both sexes were used for the rodent A experiment; for all other
experiments only males were used.
Slice preparation. Parasagittal hippocampal slices (400 m) were pre-
pared after decapitation under deep isoflurane-induced anesthesia. After
dissection in ice-cold artificial CSF (ACSF) containing (in mM) 126
NaCl, 3KCl, 1.25NaH2PO4,2MgSO4,2CaCl2, 25NaHCO3,10glucose,pH
7.2–7.4, bubbled with carbogen gas (95% O2, 5% CO2), slices were main-
tainedat roomtemperature (2225°C) in a submerged-styleholding cham-
ber for at least 1 h and then incubated in drug/control solutions. For
recording, slices were transferred to an interface-style recording chamber
maintained at 33–35°C and superfusedwithACSF at a rate of 2ml/min, and
recording started at least 15 min after the slices were transferred.
Pharmacology. Rodent A1–42 (rA1–42) was dissolved in ACSF to a
concentration of 10 M and frozen in aliquots. Single aliquots were de-
frosted and sonicated for 11 min before final dilution to 500 nM for slice
incubation.HumanA1–42 (hA1–42) was freshly prepared on the day of
the experiment. It was initially dissolved in ACSF to a concentration of 5
M. Aliquots were then sonicated for 11 min before final dilution to 220
nM in ACSF.
Hippocampal slices were incubated in a submerged-style holding
chamber in ACSF with or without A1–42 or A42–1 for 1–3 h before
recording. Perfusion with a half-concentration of the drug continued
after slices were transferred to the interface chamber.
AR-A014418 was dissolved in DMSO at 100 mM concentration and
stored in frozen aliquots. For slice incubation, single aliquots of AR-
A014418 were defrosted and diluted to a final concentration of 1 M in
ACSF. Slices were incubated for 30–45 min in AR-A014418 before the
addition of A1–42 or control ACSF.
To block GABAA receptor-mediated inhibition in some experiments,
gabazine (SR 95531) was bath applied at 100 nM concentration to slices
from which the CA3 had been removed.
hA1–42, hA42–1, rA1–42, and gabazine were purchased from Tocris
Bioscience; AR-A014418 was obtained from Sigma Aldrich.
Electrophysiological protocols. Extracellular field recordings from CA1
were made with an Axoclamp-2A amplifier in bridge mode, and data
were acquired with an ITC-16 A/D board (Instrutech) using Igor Pro
software (WaveMetrics). Borosilicate glass recording electrodes were
filled with ACSF. Recording and stimulation electrodes were positioned
in the stratum radiatum of CA1. Synaptic efficacy was monitored by
stimulating the Schaffer collaterals at 0.2 Hz (50 s, 20–60 A) with a
monopolar tungsten electrode connected to a stimulus isolator unit
(ISO-Flex, A.M.P.I.). Stimulation strength was set to elicit a field EPSP
(fEPSP) of half-maximal amplitude. fEPSP slopes were monitored for a
baseline period of at least 15 min. If synaptic transmission was stable (
15% change in fEPSP slopes over 15 min), a single high-frequency stim-
ulus train was delivered (100 Hz for 1 s). To measure paired-pulse ratio
both before and after LTP induction, two 50s pulses with an interpulse
interval of 40 ms were given at a low stimulation strength.
Protein extraction and Western blot analysis. Slices were prepared as
described above from wild-type and Tau/ mice and incubated in
ACSF with or without 220 nM hA1–42 for 2 h. A subset of slices was
preincubated in 1 M AR-A014418 for 30 min. The hippocampus was
dissected from each slice and immediately frozen at 80°C. Total
protein was extracted by homogenizing hippocampal slices in radio-
immunoprecipitation assay buffer (Sigma Aldrich) supplemented
with phosphatase inhibitors (PhosSTOP, Roche) and protease inhib-
itors (Complete Mini Protease Inhibitor Cocktail, Roche), followed
by brief microcentrifugation. Protein concentrations were deter-
mined using the Bradford method. Two micrograms of total protein
were separated on 3–8%Tris acetate polyacrylamide gels (Invitrogen)
and transferred to a polyvinylidene fluoride membrane. Membranes
were blocked in phosphate buffered saline containing 0.1% Tween 20
and 10% milk and probed with primary antibody. Membranes were
probed initially with an anti-phospho-tau primary antibody (AT8,
1:1000; Thermo Scientific) before stripping in Restore buffer (Pierce)
and reprobing with a primary antibody to detect total tau (Tau5, 1:1000;
Fitzgerald). Primary antibody binding was detected using an anti-mouse
HRP-conjugated secondary antibody (Bio-Rad) and ECL Plus reagent
(GE Healthcare) apposed to photographic film (CL-Xposure film,
Thermo Scientific). Films were digitized and optical densities were de-
termined using ImageJ (v1.43u; National Institutes of Health). To con-
trol for between-membrane variation, all samples from an individual
mouse were run on a single gel, and optical densities were expressed as
ratios of phospho/total tau normalized to the respective ACSF-only con-
dition. Values presented are the mean of duplicate Western blots.
Data analysis. Changes in synaptic efficacy were estimated using the
mean fEPSP slopes (measured from themiddle third of the rising slope of
the fEPSP) 30–45 min after high-frequency stimulation normalized to
themean fEPSP slope during the last 5min of baseline recording. Paired-
pulse ratiowas expressed as themean ratio of the amplitude of the second
fEPSP to the amplitude of the first fEPSP (average of five paired pulses).
Data were analyzed using Igor Pro, Matlab, and SPSS and are given as
mean  SEM. Statistical significance was assessed using the Student’s t
test or one-way ANOVA, followed by post hoc analysis with Bonferroni
corrections when applicable. Unless otherwise stated, numbers (N) refer
to the number of slices obtained from at least six animals. Experiments in
Figure 1 were performed blind such that the experimenter was not aware
of genotype. In a subset (approximately half) of experiments in Figure 2,
the experimenter was unaware of drug and genotype. As the average and
variability of blind and nonblind experiments were similar, these data
were pooled.
Results
LTP in A1–42-exposed slices from Tau
/mice
First, we wanted to confirm that A1–42 inhibits LTP in hip-
pocampal slices from wild-type mice. We monitored fEPSPs
evoked by extracellular stimulation of the Schaffer collateral
pathway and induced LTP using high-frequency stimulation
(100 Hz for 1 s). In slices pretreated with 500 nM rA1–42 for 1–3
h, LTP was almost completely blocked (control: 153 12%,N
19; rA1–42: 112  11%, N  21; t test, p  0.05) (Fig. 1a,c).
Similarly, hA1–42 also strongly impaired LTP (control: 137 
5%, N  11; hA1–42: 115  5%, N  9; t test, p  0.01) (Fig.
2a,c), consistent with previous reports (Walsh et al., 2002; Wang
et al., 2004; Townsend et al., 2006). This was a specific effect of
hA1–42, because slices pretreatedwith a control peptide contain-
ing the hA peptide sequence in reverse order (hA42–1) showed
a synaptic potentiation (137 7%,N 13) (Fig. 2a,c) equivalent
to that in control slices (t test, p  0.49). These results demon-
strate that, in wild-typemice, acute application of A1–42 impairs
one or more of the cellular mechanisms necessary for LTP.
To investigate a possible interaction between A and tau, we
tested the effect of A1–42 on LTP inTau
/mice (Dawson et al.,
2001). Slices incubated in control solution showed normal levels
of LTP and, remarkably, slices preincubated in rA1–42 showed
LTP of similar magnitude (control: 157 11%,N 11; rA1–42:
145 12%,N 15; t test, p 0.51) (Fig. 1b,c). Equivalent results
were obtained using hA1–42 (control: 138 5%,N 15; hA1–42:
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138  7%, N  9; t test, p  0.48) (Fig.
2b,c). Univariate ANOVA revealed amain
effect of treatment, as well as a genotype–
treatment interaction for both rodent and
human A1–42 (rA1–42: F(1,65)  3.23,
p  0.05; hA1–42: F(1,40)  5.03, p 
0.05), resulting from a significant effect of
A in wild-type slices.
To investigate whether this result could
be caused by different basic synaptic prop-
erties between wild-type and Tau/mice,
wemeasured the synaptic input–output re-
lationshipandpaired-pulse ratio (PPR).We
found no difference in synaptic input–out-
put relationships between wild-type and
Tau/ mice, indicating equivalent basal
synaptic transmission (supplemental
Fig. 1a, available at www.jneurosci.org
as supplemental material). Moreover,
we observed no difference in the PPR
(supplemental Fig. 1b) between wild-type
and Tau/ mice [wild-type PPR before
LTP: 1.67  0.05, PPR after LTP: 1.68 
0.10, N  12; Tau/ PPR before LTP:
1.63  0.11, PPR after LTP: 1.72  0.06,
N  10; repeated measures ANOVA re-
vealed no effect of genotype (between-
subjects factor F(1,17) 0.323; p 0.58) on
PP value before or after LTP induction
(within-subjects factor F(1,17)  0.55; p 
0.47] (supplemental Figure 1). There was
also no significant difference in post-tetanic
potentiation (PTP) between wild-type and
Tau/ mice (wild-type PTP: 193  9%,
N  28 mice, Tau/ PTP: 211  10%,
N  18 mice, t test p  0.18) (Fig. 1a,b,
2a,b). To confirm that the LTP results were
not caused by differences in GABAergic in-
hibition, experiments were repeated
with equivalent results in the presence
of 100 nM gabazine in slices with the
CA3 removed (supplemental Fig. 2,
available at www.jneurosci.org as sup-
plemental material). Altogether, these
results suggest that differences in basic
synaptic properties are unlikely to account for the lack of
A1–42-induced impairment of LTP in Tau
/ mice.
Given that NFTs comprising hyperphosphorylated tau are a
prominent AD pathology alongside A plaques, we asked
whether the A1–42-induced impairment of LTP is associated
with tau phosphorylation and requires activity of GSK-3, a
serine/threonine kinase known to phosphorylate tau protein
(Ishiguro et al., 1993). We used AR-A014418, which is a highly
specific GSK-3 inhibitor that does not significantly inhibit closely
related kinases such as cdk2 or cdk5 (Bhat et al., 2003). First, to
test whether hA1–42 increases tau phosphorylation and AR-
A014418 inhibits tau phosphorylation under our experimental
conditions, we used Western blot analysis of hippocampal tissue
from slices incubated in ACSF with or without 220 nM hA1–42.
In a subset of experiments, slices were preincubated in 1 M
AR-A014418 to inhibit GSK-3 activity. A significant effect of
treatment on the ratio of phosphorylated tau to total tau was
found (ANOVA, F(2,22) 3.99 p 0.05) (Fig. 3). Incubationwith
Figure 1. Rodent A1–42 does not reduce LTP in slices of Tau
/ mice. a, b, Hippocampal Schaffer collateral-CA1 LTP in
wild-type (a) and Tau/mice (b) in control ACSF (black) or after incubationwith rA1–42 (red). The insets show superimposed
example traces before and 40 min after high-frequency stimulation for each condition. Scale bars: 5 ms, 200V. c, Summary of
results 40–45 min after high-frequency stimulation. Error bars are SEM; *p  0.05. The numbers of slices are shown in
parentheses.
Figure 2. Human A1–42 does not reduce LTP in slices of Tau
/ mice. a, b, Hippocampal Schaffer collateral-CA1 LTP in
wild-type (a) and Tau/mice (b) in control ACSF (black), or after incubationwith hA1–42 (red) or the control peptide hA42–1
(gray). The insets show superimposed example traces before and40min after high-frequency stimulation for each condition. Scale
bars: 5 ms, 200 V. c, Summary of results 40–45 min after high-frequency stimulation. Error bars are SEM; **p 0.01. The
numbers of slices are shown in parentheses.
Figure 3. A specific inhibitor of GSK-3 reduces A1– 42-induced phosphorylation of tau.
a, Example Western blot showing immunoreactivity to Tau5 (total Tau) and AT8 (phos-
phorylated Tau). b, Pooled data for AT8/Tau5 ratios normalized to immunoreactivity ob-
served in control conditions in each mouse; *p 0.05; **p 0.01. The numbers of mice
are shown in parentheses.
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hA1–42 significantly increased tau phosphorylation in hippocam-
pal tissue compared with control slices (AT8/Tau5 ratio 1.53
0.26, N 10, one-sample t test, p 0.05), and the phosphorylation
ratio in slicespreincubatedwithAR-A014418was significantly lower
than those incubatedwith hA1–42 alone (AT8/Tau5 ratio 0.72
0.14, N  9, two-sample t test, p  0.01). Slices exposed to 1 M
AR-A014418 alone showed tau phosphorylation equivalent to that
observed in control conditions (AT8/Tau5 ratio 0.96 0.16,N
4).Next,we testedwhether this concentrationofAR-A014418 could
block thehA1–42-induced impairmentofLTP.Whenhippocampal
slices from wild-type mice were pre-exposed to 1 M AR-A014418
for 30 min before incubation with hA1–42, we observed LTP of a
magnitude equivalent to that in control slices (control: 134 6%,
N 9, hA1–42: 135 5%,N 9, t test p 0.58) (Fig. 4a,b) and in
slices exposed to AR-A014418 alone (134 6%, N 9, t test p
0.51, compared with control) (Fig. 4a,b). This recovery of LTP was
attributable to AR-A014418, since LTP was not observed in slices
pre-exposed tovehicle (0.01%DMSO) for30minbefore incubation
with hA1–42 (supplemental Fig. 3a,b), and vehicle alone did not
affect LTP (supplemental Fig. 3a,b). The finding that AR-A014418
completely blocked the hA1–42-induced, augmented tau phos-
phorylation, aswell as impairmentofLTP, suggests that activationof
GSK-3 and its phosphorylation of tau are required for the effect of
A1–42 on synaptic plasticity.
Discussion
Two principal findings emerge from this work. First, in Tau/
mice, neither the rodent nor human version of A1–42 impaired
hippocampal LTP, in contrast to the robust impairment of LTP
they caused in slices from wild-type mice. Second, a specific in-
hibitor of the tau kinase GSK-3 prevented both the augmented
tau phosphorylation and the impairment of LTP that were oth-
erwise seen following A1–42 treatment in wild-type mice.
Because cognitive decline in early AD is associated with pa-
thology in the medial temporal lobe (Braak and Braak, 1991), we
investigated LTP at the hippocampal
CA3-CA1 synapse, a widely accepted cel-
lular model for learning and memory.
Our confirmation that A1–42 impaired
LTP in slices from wild-type mice is in
agreement with a wealth of previous re-
ports (Cullen et al., 1997; Lambert et al.,
1998; Chen et al., 2002; Walsh et al., 2002;
Wang et al., 2004; Townsend et al., 2006)
showing that soluble A oligomers have
an inhibitory effect on LTP. It also sug-
gests that, under our experimental condi-
tions, A assembled into the oligomeric
complexes thought to be the synaptotoxic
form of the peptide. We show that the
magnitude of LTP is not reduced in slices
from Tau/ mice exposed to either hu-
man or rodent A1–42. This suggests that
tau protein is one element required for the
synaptotoxic effects of A1–42, consistent
with the finding that tau-depleted neu-
rons do not degenerate in the presence of
A (Rapoport et al., 2002). The similar
synaptic input–output relationships and
unchanged paired-pulse ratios with LTP
in wild-type andTau/mice that we ob-
served suggests that this result is not
caused by different presynaptic properties
in Tau/ mice, but that the absence of
tau uncouples A from its downstream effects that impair the
postsynaptic mechanisms required for LTP. In support of this
postsynaptic interpretation, a dendritic role for tau in mediating
A toxicity was recently reported (Ittner et al., 2010). Neverthe-
less, this does not exclude a contribution of presynaptic mecha-
nisms; for example, A-induced deficits in axonal transport are
prevented in Tau/ neurons (Vossel et al., 2010).
It is a priority to establish which molecular pathways underlie
the A1–42-induced impairment of LTP. We found that the spe-
cific GSK-3 inhibitor AR-A014418 can prevent impairment of
LTP by hA1–42 in wild-type slices. This suggests that GSK-3, via
its subsequent phosphorylation of tau (Ishiguro et al., 1993), is a
key component in the pathway by which A exerts its pathogenic
downstream effects on LTP, similar to A-mediated neurode-
generation (Tackenberg and Brandt, 2009). In support of this, we
demonstrate that inhibition of GSK-3 prevents the augmented
tau phosphorylation seen following incubation in A alone.
However, while our results show that A-induced impairment of
LTP is associated with increased levels of tau phosphorylation
and that a specific inhibitor ofGSK-3 blocks both increased phos-
phorylation and impairment of LTP, they do not provide conclu-
sive evidence that phosphorylated tau protein mediates this
impairment. The results also do not exclude the involvement of
other kinases previously implicated in the A-induced impair-
ment of LTP, including c-Jun N-terminal kinase, cdk5, p38
mitogen-activated protein kinase (Wang et al., 2004), and pro-
tein kinase A (Vitolo et al., 2002). Nevertheless, the complete
recovery of LTP magnitude in the presence of AR-A014418 is
striking.
Previous studies have shown a correlation between behavior
and synaptic plasticity, with both learning and LTP being im-
paired in the same animal model of AD (Chapman et al., 1999;
Ste´phan et al., 2001). Combined with the behavioral findings of
Roberson et al. (2007), the present data are the first to link LTP
Figure 4. The specific GSK-3 inhibitor AR-A014418 prevents impairment of LTP by human A1–42 in wild-type slices. a,
Hippocampal Schaffer collateral-CA1 LTP in wild-type mice in control ACSF (black) or after incubation with AR-A014418 alone
(gray) or AR-A014418 followed by incubation with hA1–42 (blue). The insets show superimposed example traces before and 35
min after high-frequency stimulation for each condition. Scale bars: 5 ms, 200 V. b, Summary of results 30–35 min after
high-frequency stimulation. Error bars are SEM. The numbers of slices are shown in parentheses.
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and behavior through tau protein. This both strengthens the link
between synaptic plasticity and memory and suggests a mecha-
nism underlying the cognitive dysfunction in early AD. Never-
theless, our data were obtained with acute application of
synthetic A peptides, whereas the lack of cognitive deficits was
found in hAPP-overexpressing and tau knock-out mice (Rober-
son et al., 2007); there may be subtle differences between chronic
in vivo and acute in vitro exposure. For example, 1–2 d APP
overexpression or A exposure can reduce spine density, whereas
1 h exposure to A peptides alters the structural plasticity of
individual spines (Wei et al., 2010).
Overall, the findings presented here indicate that the absence
of tau prevents the synaptic dysfunction induced by A1–42, and
support previous suggestions that tau acts downstream of A
(Hardy and Selkoe, 2002), although parallel pathways remain
possible (Small and Duff, 2008). These results, using acute expo-
sure to soluble A1–42, may be relevant to early AD, when synap-
tic dysfunction is present but before extensive plaque formation
has occurred. However, later in the disease process the absence of
functional tau protein may render the brain more vulnerable to
A (Dawson et al., 2010). Nevertheless, the molecular cascades
being uncovered suggest that GSK-3 might be a potential drug
target for treating synaptic dysfunction and, hence, improving
cognitive function during early AD.
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